

## ASX ANNOUNCEMENT

ASX: 1AI | 9 February 2026

### Highlights

- **Algorae finalises Licence & Supply Agreement ("LSA") with Cadila Pharmaceuticals to launch two generic medicines targeting cardiovascular and metabolic disorders in Australia and New Zealand ("ANZ").**
- **Cadila to develop and manufacture product; Algorae to act as TGA sponsor and commercialise under its AlgoraeRx commercial division.**
- **Agreement complements existing oncology-focused licensing agreement with Sakar Healthcare Limited for five generic oncology medicines in ANZ.**
- **Follows recent distribution agreement with Dr. Reddy's to supply Capecitabine 500 mg tablets into the Australian market, with first shipment received January 2026.**

Following the binding term sheet announced on 20 October 2025, AI-enabled pharmaceutical company Algorae Pharmaceuticals Ltd (ASX: 1AI) ("Algorae" or "the Company") is pleased to announce that it has executed the definitive **Licence & Supply Agreement ("LSA")** with **Cadila Pharmaceuticals Limited ("Cadila")**, for the commercialisation of two generic medicines for cardiovascular and metabolic disorders in the Australia and New Zealand markets.

Under the terms of the LSA, Cadila will be responsible for product development and manufacture, while Algorae, through its wholly owned subsidiary AlgoraeRx Pty Ltd, will hold Therapeutic Goods Administration ("TGA") sponsorship, manage regulatory submissions and oversee market access and commercialisation activities across ANZ.

The Cadila agreement further strengthens Algorae's rapidly growing commercial portfolio, which now includes:

- An exclusive commercial licensing agreement with Sakar Healthcare Limited to launch five generic oncology medicines in ANZ, complementing the Company's oncology R&D program at Peter MacCallum Cancer Centre.
- A distribution agreement with Dr. Reddy's Laboratories Ltd to supply the chemotherapy medicine Capecitabine 500 mg tablets into the Australian market, with the first shipment received in January 2026.

Collectively, these partnerships establish a multi-partner, multi-therapy commercial platform spanning oncology, cardiovascular and metabolic diseases, and provide Algorae with a diversified base of products targeting hospitals, pharmacies and other institutional customers in Australia and New Zealand.

Algorae will now commence TGA registration planning and documentation for the Cadila products and will update shareholders on submission timing, anticipated launch windows and expected revenue contribution as the program advances.

Through its AlgoraeRx subsidiary, the Company continues to progress additional commercial opportunities and will provide further updates as these initiatives advance.

### About Cadila Pharmaceuticals Limited

**Cadila Pharmaceuticals Limited** is one of India's largest privately held pharmaceutical companies, with vertically integrated operations across active pharmaceutical ingredients ("APIs"), finished formulations, contract research and manufacturing services. Headquartered in Ahmedabad, Gujarat, India.

Cadila operates state-of-the-art GMP-compliant manufacturing facilities. Cadila's products are marketed in over 100 countries across Asia, Africa, Europe and the Americas, supported by a global workforce of more than 9,000 professionals. Its research and development division comprises over 350 scientists working across key therapeutic areas such as respiratory, cardiometabolic, gastrointestinal, oncology, anti-infective and pain management.

Founded in 1951 by the late Indravadan A. Modi, Cadila has built a long-standing reputation for combining scientific innovation with social responsibility. Guided today by Dr Rajiv Modi, Chairman and Managing Director, Cadila continues to advance its founding mission of "affordable innovation" through the discovery, development and global distribution of high-quality medicines. With a diversified portfolio, strong regulatory track record and commitment to sustainable growth, Cadila Pharmaceuticals remains a trusted partner in improving access to healthcare worldwide.

**Authorised for release by the Board of Directors of Algorae Pharmaceuticals Ltd**

**END.**

### Corporate and Media Enquiries

Mr David Hainsworth

Executive Chairman

E: [inquiries@algoraepharma.com](mailto:inquiries@algoraepharma.com)

### About Algorae Pharmaceuticals

Algorae Pharmaceuticals Ltd (ASX: 1AI) is an AI-enabled pharmaceutical company with a dual focus on drug-combination discovery and pharmaceutical commercialisation. The Company's proprietary AI platform, AlgoraeOS, applies artificial intelligence to identify synergistic drug combinations and inform preclinical experimental design.

In parallel, Algorae operates a commercialisation business, AlgoraeRx, which sources, licenses and supplies generic and specialty medicines in Australia and New Zealand through manufacturing partners and established distribution channels. Algorae collaborates with research institutions and industry partners to translate AI-predicted therapies and expand patient access to high-quality medicines.

For more information visit [www.algoraepharma.com](http://www.algoraepharma.com) or follow @algoraepharma on X or LinkedIn.

#### Forward-looking Statements

This document may contain certain forward-looking statements, relating to Algorae's business, which can be identified by the use of forward-looking terminology such as "promising," "probable", "plans," "anticipated," "will," "project," "believe," "forecast," "expected," "estimated," "targeting," "aiming," "set to," "potential," "seeking to," "goal," "could provide," "intends," "is being developed," "could be," "on track," or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates, nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales.

In particular, management's expectations regarding the approval and commercialisation of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialise, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated, or expected. Algorae is providing this information and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.